$ASND Analysis and Prediction for Ascendis Pharma A/SChart Overview:
Instrument: Ascendis Pharma A/S (ASND)
Timeframe: 1-Hour Chart
Key Features:
Dark Pool Level: Highlighted at $140 (critical resistance).
Pivot Resistance: R1 ($141.91) as a significant resistance level.
Support Levels: S1 ($130.43), MY TGT ($127.07), and S2 ($124.47).
Trendlines:
Gre
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−7.13 USD
−408.97 M USD
393.35 M USD
59.38 M
About Ascendis Pharma A/S
Sector
Industry
CEO
Jan Møller Mikkelsen
Website
Headquarters
Hellerup
Founded
2006
FIGI
BBG007R7VNC1
Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. It specializes in its TransCon technologies to develop new therapies that address unmet medical needs. The company was founded by Jan Moller Mikkelsen, Dirk Vetter, and Harald Rau on September 21, 2006 and is headquartered in Hellerup, Denmark.
ASND Stock-Weekly 26 EMA pointing upwards.
-Price on a previous key level that was test many times.
Long positions preferred.
-15 minute sideways movement with a shakeout forming a reverse head and shoulders pattern with a bullish breakout.
-Price entering the range after the breakout forming a MACD dive
ASND Ascendis Pharma A/S Options Ahead of EarningsAnalyzing the options chain and the chart patterns of ASND Ascendis Pharma A/S prior to the earnings report this week,
I would consider purchasing the 100usd strike price Calls with
an expiration date of 2023-9-15,
for a premium of approximately $6.45.
If these options prove to be profitable prior
ASND ( NASDAQ BIOTECH) rises on earnings and FDA submissionNASDAQ:ASND
as can be seen on the hourly chart ASND is in an uptrend
recent earnings were a good beat,
RSI is quite high and it is at one than one STD above
the multi-session VWAP.
ASND is on watch for a pullback to find an entry
as it has high upside.
$ASND can rise in the next daysContextual immersion trading strategy idea.
The demand for shares of Ascendis Pharma A/S looks higher than the supply.
This and other conditions can cause a rise in the share price in the next days.
So I opened a long position from $117,86;
stip-loss — $114,88
Information about take-profits will
ASCENDIS PHARMA ON THE CLIFF EDGEKEEP ALERTS SET FOR A BREAK OF $105, WHICH COULD RESULT IN A VERY NASTY FALL BACK DOWN TO THE GAP UP LEVEL $75,
AVERAGE ANALYSTS ESTIMATE $162.20
AVERAGE ANALYSTS RECOMMENDATION BUY
COMPANY PROFILE
Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candi
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.